Aileron Therapeutics, Inc. previously announced on April 25, 2022 that Richard J. Wanstall, the company's Chief Financial Officer, principal financial officer and principal accounting officer, notified the company of his resignation, effective May 6, 2022. On June 5, 2022, the Board of Directors of the company appointed Manuel Aivado, M.D., Ph.D., the company's President and Chief Executive Officer to serve as the company's principal financial officer and principal accounting officer. Dr. Aivado, age 52, has served as the President and Chief Executive Officer and as a member of the board of directors since September 2018.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | +1.92% | -4.56% | +3.00% |
05-16 | Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
05-16 | Aileron Therapeutics, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.00% | 66.17M | |
+16.86% | 123B | |
+13.30% | 107B | |
-6.26% | 24.01B | |
+1.95% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-12.12% | 16.23B | |
+1.63% | 13.43B | |
+22.59% | 11.32B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer